Aurinia Pharmaceuticals
(NASDAQ) AUPH
Aurinia Pharmaceuticals Financials at a Glance
Market Cap
$1.87B
Revenue (TTM)
$283.06M
Net Income (TTM)
$287.20M
EPS (TTM)
$2.08
P/E Ratio
6.77
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Price
$14.00
Volume
22,607
Open
$14.10
Price
$14.00
Volume
22,607
Open
$14.10
Previous Close
$14.00
Daily Range
$13.87 - $14.12
52-Week Range
$6.83 - $16.54
Dividend
$0.00
Beta (Volatility)
1.14 (Average)
Price
$14.00
Volume
22,607
Open
$14.10
Previous Close
$14.00
Daily Range
$13.87 - $14.12
52-Week Range
$6.83 - $16.54
AUPH News
AUPH: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aurinia Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
128
CEO
Peter S. Greenleaf, MBA
Website
www.auriniapharma.comHeadquarters
Edmonton, BC V8Z 7X8, CA
AUPH Financials
Key Financial Metrics (TTM)
Gross Margin
88%
Operating Margin
37%
Net Income Margin
1%
Return on Equity
60%
Return on Capital
16%
Return on Assets
38%
Earnings Yield
14.77%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.87B
Shares Outstanding
132.97M
Volume
22.61K
Short Interest
0.00%
Avg. Volume
974.56K
Financials (TTM)
Gross Profit
$250.39M
Operating Income
$104.91M
EBITDA
$127.76M
Operating Cash Flow
$135.66M
Capital Expenditure
$252.00K
Free Cash Flow
$135.41M
Cash & ST Invst.
$398.00M
Total Debt
$74.81M
Aurinia Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$77.11M
+28.8%
Gross Profit
$68.64M
+26.4%
Gross Margin
89.01%
N/A
Market Cap
$1.87B
N/A
Market Cap/Employee
$14.39M
N/A
Employees
130
N/A
Net Income
$210.79M
+14651.2%
EBITDA
$47.07M
+555.5%
Quarterly Fundamentals
Net Cash
$323.19M
+15.8%
Accounts Receivable
$41.45M
+13.4%
Inventory
$45.69M
+16.5%
Long Term Debt
$57.22M
-11.0%
Short Term Debt
$17.59M
+16.7%
Return on Assets
38.21%
N/A
Return on Invested Capital
15.95%
N/A
Free Cash Flow
$44.50M
+48.1%
Operating Cash Flow
$44.57M
+48.0%